Zhengye Biotechnology (ZYBT) - יתרת חוב לטווח ארוך להון עצמי

Zhengye Biotechnology (ZYBT) is exposed to the US-China trade conflict, which threatens delisting and export bans. This price action chart confirms volatility, with the indicator standing at 0.04. The company's growth relies on the modernization of China's veterinary sector and the demand for swine vaccines. Production capacity is supported by reactor sterilization and precise equipment calibration at biological product manufacturing plants.

By expanding domestic veterinary drug production through distribution without mergers, Zhengye Biotechnology (ZYBT) is optimizing its financing structure. The historical long-term debt-to-equity ratio quantifies the company's reliance on long-term borrowings relative to its own equity, where a lower ratio minimizes default risks but may slow the pace of business expansion during periods of market growth.